vs
Side-by-side financial comparison of GRIFFON CORP (GFF) and Hologic (HOLX). Click either name above to swap in a different company.
Hologic is the larger business by last-quarter revenue ($1.0B vs $649.1M, roughly 1.6× GRIFFON CORP). Hologic runs the higher net margin — 17.1% vs 9.9%, a 7.2% gap on every dollar of revenue. On growth, GRIFFON CORP posted the faster year-over-year revenue change (2.6% vs 2.5%). Hologic produced more free cash flow last quarter ($215.2M vs $99.3M). Over the past eight quarters, Hologic's revenue compounded faster (1.5% CAGR vs -1.8%).
Griffon Corporation is a multinational conglomerate headquartered in New York City. It operates as a diversified management and holding company. The company has four subsidiaries: Ames True Temper, ClosetMaid, Clopay Building Products, and CornellCookson. Griffon has been publicly traded since 1961 and is listed on the New York Stock Exchange as a component stock of the S&P SmallCap 600, S&P Composite 1500, and Russell 2000 indices.
Hologic, Inc. is an American medical technology company primarily focused on women's health; it sells medical devices for diagnostics, surgery, and medical imaging.
GFF vs HOLX — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $649.1M | $1.0B |
| Net Profit | $64.4M | $179.1M |
| Gross Margin | 41.1% | 56.0% |
| Operating Margin | 17.5% | 22.6% |
| Net Margin | 9.9% | 17.1% |
| Revenue YoY | 2.6% | 2.5% |
| Net Profit YoY | -9.1% | -10.9% |
| EPS (diluted) | $1.41 | $0.79 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $649.1M | $1.0B | ||
| Q3 25 | $662.2M | $1.0B | ||
| Q2 25 | $613.6M | $1.0B | ||
| Q1 25 | $611.7M | $1.0B | ||
| Q4 24 | $632.4M | $1.0B | ||
| Q3 24 | $659.7M | $988.0M | ||
| Q2 24 | $647.8M | $1.0B | ||
| Q1 24 | $672.9M | $1.0B |
| Q4 25 | $64.4M | $179.1M | ||
| Q3 25 | $43.6M | $187.2M | ||
| Q2 25 | $-120.1M | $194.9M | ||
| Q1 25 | $56.8M | $-17.4M | ||
| Q4 24 | $70.9M | $201.0M | ||
| Q3 24 | $62.5M | $178.6M | ||
| Q2 24 | $41.1M | $194.5M | ||
| Q1 24 | $64.1M | $169.9M |
| Q4 25 | 41.1% | 56.0% | ||
| Q3 25 | 41.7% | 55.6% | ||
| Q2 25 | 43.2% | 56.3% | ||
| Q1 25 | 41.2% | 37.5% | ||
| Q4 24 | 41.8% | 56.8% | ||
| Q3 24 | 39.9% | 56.4% | ||
| Q2 24 | 38.5% | 55.4% | ||
| Q1 24 | 40.2% | 53.3% |
| Q4 25 | 17.5% | 22.6% | ||
| Q3 25 | 18.0% | 22.6% | ||
| Q2 25 | -20.5% | 24.9% | ||
| Q1 25 | 16.5% | -0.7% | ||
| Q4 24 | 17.7% | 22.5% | ||
| Q3 24 | 16.9% | 23.3% | ||
| Q2 24 | 13.8% | 24.1% | ||
| Q1 24 | 16.9% | 20.7% |
| Q4 25 | 9.9% | 17.1% | ||
| Q3 25 | 6.6% | 17.8% | ||
| Q2 25 | -19.6% | 19.0% | ||
| Q1 25 | 9.3% | -1.7% | ||
| Q4 24 | 11.2% | 19.7% | ||
| Q3 24 | 9.5% | 18.1% | ||
| Q2 24 | 6.3% | 19.2% | ||
| Q1 24 | 9.5% | 16.7% |
| Q4 25 | $1.41 | $0.79 | ||
| Q3 25 | $1.04 | $0.84 | ||
| Q2 25 | $-2.65 | $0.86 | ||
| Q1 25 | $1.21 | $-0.08 | ||
| Q4 24 | $1.49 | $0.87 | ||
| Q3 24 | $1.29 | $0.75 | ||
| Q2 24 | $0.84 | $0.82 | ||
| Q1 24 | $1.28 | $0.72 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $95.3M | $2.4B |
| Total DebtLower is stronger | — | $2.5B |
| Stockholders' EquityBook value | $108.9M | $5.2B |
| Total Assets | $2.1B | $9.2B |
| Debt / EquityLower = less leverage | — | 0.48× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $95.3M | $2.4B | ||
| Q3 25 | $99.0M | $2.2B | ||
| Q2 25 | $107.3M | $1.9B | ||
| Q1 25 | $127.8M | $1.6B | ||
| Q4 24 | $152.0M | $2.0B | ||
| Q3 24 | $114.4M | $2.3B | ||
| Q2 24 | $133.5M | $2.4B | ||
| Q1 24 | $123.0M | $2.2B |
| Q4 25 | — | $2.5B | ||
| Q3 25 | — | $2.5B | ||
| Q2 25 | $1.5B | $2.5B | ||
| Q1 25 | $1.5B | $2.5B | ||
| Q4 24 | $1.5B | $2.5B | ||
| Q3 24 | $1.5B | $2.5B | ||
| Q2 24 | $1.5B | $2.5B | ||
| Q1 24 | $1.6B | $2.6B |
| Q4 25 | $108.9M | $5.2B | ||
| Q3 25 | $74.0M | $5.0B | ||
| Q2 25 | $63.9M | $4.8B | ||
| Q1 25 | $214.7M | $4.6B | ||
| Q4 24 | $227.8M | $4.8B | ||
| Q3 24 | $224.9M | $5.1B | ||
| Q2 24 | $223.5M | $5.0B | ||
| Q1 24 | $202.2M | $4.8B |
| Q4 25 | $2.1B | $9.2B | ||
| Q3 25 | $2.1B | $9.0B | ||
| Q2 25 | $2.1B | $8.8B | ||
| Q1 25 | $2.3B | $8.5B | ||
| Q4 24 | $2.3B | $8.7B | ||
| Q3 24 | $2.4B | $9.2B | ||
| Q2 24 | $2.4B | $8.9B | ||
| Q1 24 | $2.4B | $8.7B |
| Q4 25 | — | 0.48× | ||
| Q3 25 | — | 0.50× | ||
| Q2 25 | 22.71× | 0.52× | ||
| Q1 25 | 7.16× | 0.55× | ||
| Q4 24 | 6.48× | 0.53× | ||
| Q3 24 | 6.78× | 0.49× | ||
| Q2 24 | 6.74× | 0.51× | ||
| Q1 24 | 7.84× | 0.53× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $107.0M | $229.9M |
| Free Cash FlowOCF − Capex | $99.3M | $215.2M |
| FCF MarginFCF / Revenue | 15.3% | 20.5% |
| Capex IntensityCapex / Revenue | 1.2% | 1.4% |
| Cash ConversionOCF / Net Profit | 1.66× | 1.28× |
| TTM Free Cash FlowTrailing 4 quarters | $278.9M | $1.0B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $107.0M | $229.9M | ||
| Q3 25 | $75.0M | $355.1M | ||
| Q2 25 | $123.1M | $343.3M | ||
| Q1 25 | $16.5M | $169.4M | ||
| Q4 24 | $142.9M | $189.3M | ||
| Q3 24 | $72.1M | $367.0M | ||
| Q2 24 | $122.1M | $405.8M | ||
| Q1 24 | $39.8M | $292.4M |
| Q4 25 | $99.3M | $215.2M | ||
| Q3 25 | $62.4M | $341.4M | ||
| Q2 25 | $114.4M | $330.5M | ||
| Q1 25 | $2.8M | $153.9M | ||
| Q4 24 | $125.5M | $172.5M | ||
| Q3 24 | $51.6M | $350.6M | ||
| Q2 24 | $107.5M | $385.3M | ||
| Q1 24 | $20.8M | $279.6M |
| Q4 25 | 15.3% | 20.5% | ||
| Q3 25 | 9.4% | 32.5% | ||
| Q2 25 | 18.6% | 32.3% | ||
| Q1 25 | 0.5% | 15.3% | ||
| Q4 24 | 19.8% | 16.9% | ||
| Q3 24 | 7.8% | 35.5% | ||
| Q2 24 | 16.6% | 38.1% | ||
| Q1 24 | 3.1% | 27.5% |
| Q4 25 | 1.2% | 1.4% | ||
| Q3 25 | 1.9% | 1.3% | ||
| Q2 25 | 1.4% | 1.3% | ||
| Q1 25 | 2.2% | 1.5% | ||
| Q4 24 | 2.8% | 1.6% | ||
| Q3 24 | 3.1% | 1.7% | ||
| Q2 24 | 2.2% | 2.0% | ||
| Q1 24 | 2.8% | 1.3% |
| Q4 25 | 1.66× | 1.28× | ||
| Q3 25 | 1.72× | 1.90× | ||
| Q2 25 | — | 1.76× | ||
| Q1 25 | 0.29× | — | ||
| Q4 24 | 2.02× | 0.94× | ||
| Q3 24 | 1.15× | 2.05× | ||
| Q2 24 | 2.97× | 2.09× | ||
| Q1 24 | 0.62× | 1.72× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GFF
| Consumer And Professional Products | $241.1M | 37% |
| Residential Repairand Remodel | $202.1M | 31% |
| International Excluding North America | $97.8M | 15% |
| Retail | $47.3M | 7% |
| Residential New Construction | $32.5M | 5% |
| Other | $14.2M | 2% |
| Industrial | $14.1M | 2% |
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
